DiagnosTear Technologies, Inc.
CCSE:DTR0.23
CAD
-0.02
(-10.00%)
ISIN
CA25244H1055
CUSIP
25244H105
Return %
Stock
S&P 500
1Y
-31.82
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Semi-annual Revenue
CAD
•
in mil. unless spec.Semi-annual Earnings Per Share
CAD
•
in mil. unless spec.Semi-annual Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- CEO
- Shimon Gross
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Vancouver Canada
- Website
- diagnostear.com
- Similar Companies
- Business
- DiagnosTear Technologies Inc. is a medical technology and ophthalmic diagnostic company that develops and commercializes point-of-care diagnostic solutions for ocular surface diseases and systemic health conditions. The company utilizes proprietary microfluidic and optical sensing technologies to analyze tear film biomarkers and ocular characteristics, enabling rapid, non-invasive diagnostic decision-making for eye care professionals. Its primary product portfolio and technology pipeline comprise TeaRx, a proprietary point-of-care diagnostic platform utilizing microfluidic collection and multi-parameter composition analysis of tear fluid; TeaRx DES, a CE-IVD approved diagnostic test kit engineered for the identification, stratification, and clinical monitoring of Dry Eye Syndrome; TeaRx Red Eye, a rapid point-of-care multiplex diagnostic panel designed for the differential diagnosis of acute ocular surface conditions, distinguishing between adenoviral conjunctivitis, allergic conjunctivitis, and herpetic keratitis; and the CLARIFY Eye Imaging Platform, a non-invasive optical ocular imaging technology engineered for needle-free blood and systemic biomarker diagnostics. The company caters to ophthalmologists, optometrists, eye care clinics, hospital outpatient departments, and point-of-care clinical laboratories across North America, Europe, and Asia. Founded in September 2013 and originating from the Israeli life sciences investment firm BioLight Life Sciences Ltd., DiagnosTear Technologies Inc. is headquartered in Vancouver, British Columbia, Canada, and conducts its core research and development, engineering, and laboratory operations through its wholly owned subsidiary, DiagnosTear Ltd., situated in Rehovot, Israel. In recent developments, the company completed a reverse takeover transaction in December 2024 to list its common shares on the Canadian Securities Exchange under the ticker symbol DTR, with concurrent listings on the Frankfurt Stock Exchange and the OTCQB Venture Market. In May 2026, DiagnosTear expanded its diagnostic footprint by acquiring exclusive worldwide commercial rights to the CLARIFY Eye Imaging Platform for needle-free systemic diagnostics. Furthermore, the company completed multi-center clinical validation trials in Israel demonstrating positive biomarker identification for its TeaRx Red Eye test, published clinical efficacy data in the peer-reviewed journal Current Eye Research, initiated pre-submission filings with the United States Food and Drug Administration, and executed international market entry strategies across Europe and India.